1Slamon DF, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her 2/neu[J], Oncogene Sience, 1987,235 (1785) : 177.
2Ye DW, Zheng JF,Qian SX. Mechanism of p53 gene mutation in the development of urologic cancer[J]. Zhonghua Vi Xue Za Zhi, 1999,74(11) :656.
3Lipponen P, Eskelinen M, Hietala K, et al. Expression of proliferating cell nuclear antigen (PC10), P53 protein and c-erbB-2 in renal adenocarcinoma[J]. Int J Cancer, 1994,57(2) :275.
4Zhang XH, Takenaka I, Sato C, et al. P53 and Her-2 alterations in renal cell carcinoma[J]. Urology, 1997,50 (4) : 636.
5Rotter M, Block T, Busch R, et al. Expression of Her-2/neu in renal cell carcinoma. Correlation with histologic subtypes and differentiation[J]. Int J Cancer, 1992,52(2) : 213.
6Stumm G, Eberwein S, Rostock-Wolf S, et al. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma is correlated with dedifferentiation and metastasis[J].IntJ Cancer,1996,69(1):17.
7Fontana LO, Garcia F, Arcas Martinez Salas I, et al. The expressiong of p53 and c-erbB-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival[J]. Arch Esp Uro1,2002,55(7) :792.
8Tamaki M, Maeda S, Deguchi T, et al. Usefulness of DNA ploidy, AgNORs, PCNA and c-erbB-2 as predictors of prognosis in patients with renal cell carcinoma[J]. Hinyokika Kiyo,1997,43(10):697.
9Sliwkowski MX, Lofgren JA, Lexis GD, et al. Nonclinical studies addressing the mechanism of action of transtuzm ab(Herceptin)[J]. Semin Oncol,1999 , 26 ( 4 Suppl ) :60.
10Ward RL, Hawkins NJ, Coomber D, et al. Antibody immunity to the Her-2/neu oneogenie protein in patients with coloreetal eaneer[J]. Humlmmunol, 1999,60(6) : 510.
